Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical data tables, integrin biology diagrams, and milestone-triggered royalty clauses make Pliant Therapeutics’ SEC disclosures a demanding read. Whether you’re tracking how bexotegrast is progressing through idiopathic pulmonary fibrosis trials or comparing R&D spend across programs, the company’s 10-K and 10-Q reports pack hundreds of biotech-specific details that many investors struggle to locate quickly.
Stock Titan’s AI solves that problem. Our engine delivers Pliant Therapeutics SEC filings explained simply: it scans each new document the moment it appears on EDGAR, then produces plain-language summaries, red-flag alerts, and side-by-side metric tables. Stay on top of Pliant Therapeutics Form 4 insider transactions in real-time, dive into a Pliant Therapeutics quarterly earnings report 10-Q filing with auto-generated trend charts, or review a Pliant Therapeutics annual report 10-K simplified down to trial timelines and cash runway—all without trawling PDFs.
Need to know when executives buy shares ahead of Phase 2 data? Our alerts surface Pliant Therapeutics executive stock transactions Form 4. Curious about dilution risk? AI pinpoints shelf-registration language in 8-Ks, giving you Pliant Therapeutics 8-K material events explained. A quick search also brings up the Pliant Therapeutics proxy statement executive compensation for insight into milestone-based bonuses, or a concise Pliant Therapeutics earnings report filing analysis to benchmark burn rate. From understanding Pliant Therapeutics SEC documents with AI to tracking Pliant Therapeutics insider trading Form 4 transactions, every disclosure you need is here, updated in seconds and organized for actionable decision-making.
- AI-powered summaries of every filing type
- Real-time EDGAR updates and customizable alerts
- Side-by-side comparisons of trial, cash, and share data
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin together report owning 3,947,807 shares of Pliant Therapeutics common stock, equal to 6.43% of the company’s outstanding shares. The filing is a Schedule 13G/A (Amendment No. 2) disclosing shared voting and dispositive power over those shares, with no sole voting or dispositive power reported.
The ownership amount is calculated using 61,386,278 shares outstanding as of May 1, 2025, per the issuer’s May 8, 2025 SEC filing. The signatories certify the shares were not acquired to change or influence control of the issuer. Signatures are dated August 14, 2025.
Morgan Stanley has filed a Schedule 13G revealing ownership of 3,737,335 Pliant Therapeutics (PLRX) common shares as of 30 Jun 2025. The stake equals 6.1 % of outstanding stock, obligating disclosure under the 5 % threshold. All voting and dispositive authority is reported as shared; the bank holds zero sole voting or disposal power, implying the position is spread across affiliated units.
The form was submitted under Rule 13d-1(b), indicating a passive investment rather than an activist intent. Morgan Stanley is classified as a “HC, CO” (parent holding company/control person). The firm certifies the shares were acquired in the ordinary course of business and not to influence control of the issuer. No other group members, transactions, or financial metrics are disclosed.
This filing adds a notable institutional holder to PLRX’s register, potentially boosting liquidity and visibility but contains no information on company fundamentals or strategy changes.
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
